We are investigating DNA damage signalling and repair factors in bladder cancer to develop new radiotherapy-based treatments and to identify markers to select the most suitable treatments for individual patients.
Our group focuses on using imaging techniques in small-scale trials with the particular ambitions of improving the mechanisms of data analysis and correlating the imaging data provided with histology and treatment outcomes.
Our research group specialises in bringing fundamental physical concepts to enhance everyday clinical practice.
We aim to deliver a step change in the effectiveness of radiotherapy through the evaluation of novel scientific approaches derived from the Institute's scientists in hypothesis driven clinical trials.
Our research focuses on finding new ways of making tumours more sensitive to radiotherapy treatment.
Mark Middleton’s research concentrates on development of new cancer drugs and on the treatment of melanoma.
Personalising gastro-intestinal cancers radiotherapy: the ultimate aim of the research of my group is to maximise clinical benefit in terms of better tumour control and reduction in toxicity after radiotherapy to enhance life expectancy of the patients.
Personalising radiotherapy using functional imaging: we apply functional and molecular imaging techniques to developing radiotherapy personalised to each patients’ individual tumour biology.
Our work focuses on the application of novel imaging modalities and on the development of radiation delivery methods. Both of these are dependent on a range of interrelated technologies.
We develop image analysis methods for quantitative analysis of medical images, specifically for a range of applications in cancer.